<SEC-DOCUMENT>0001776985-23-000044.txt : 20230629
<SEC-HEADER>0001776985-23-000044.hdr.sgml : 20230629
<ACCEPTANCE-DATETIME>20230629070955
ACCESSION NUMBER:		0001776985-23-000044
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230629
FILED AS OF DATE:		20230629
DATE AS OF CHANGE:		20230629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		231054280

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-kbnt316fpd29june2023.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i53d82dba51cc4f6d8e6f01d03eb7aa25_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE MONTH OF JUNE 2023</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER 001-39081 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">BioNTech SE<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">An der Goldgrube 12</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D-55131 Mainz</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Germany</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">+49 6131-9084-0<br></font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F&#58; Form 20&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Form 40&#8209;F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">On June 29, 2023, BioNTech SE and OncoC4, Inc.  announced that the first patient with non-small cell lung cancer (NSCLC) has been treated in a pivotal Phase 3 trial evaluating the companies&#8217; anti-CTLA-4 antibody candidate BNT316&#47;ONC-392. The trial is part of BioNTech&#8217;s strategy to initiate multiple pivotal trials in 2023 and 2024. The press release is attached hereto as Exhibit 99.1.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.560%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">BioNTech SE</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Name&#58; Dr. Sierk Poetting</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Title&#58;   Chief Operating Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; June 29, 2023</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT INDEX </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.905%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Exhibit</font></td><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">Description of Exhibit</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="a99_1230629bnt316fpd.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316&#47;ONC-392 program in Metastatic NSCLC</a></font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>a99_1230629bnt316fpd.htm
<DESCRIPTION>EX-99
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i18564c58f4f343caab4c926c9ca98685_1"></div><div style="min-height:70.56pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 99.1</font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:107%">BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316&#47;ONC-392 Program in Metastatic NSCLC </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:14.5pt">Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech&#8217;s and OncoC4&#8217;s strategic collaboration initiated in March 2023 with the aim to evaluate BNT316&#47;ONC-392 in various solid tumor indications</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:14.5pt">The randomized Phase 3 trial is expected to enroll approximately 600 patients with metastatic, immunotherapy-resistant NSCLC at clinical trial sites initially in the United States, followed by Europe and other countries and region</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:14.5pt">The trial initiation follows the FDA Fast Track Designation granted in 2022, based on Phase 1&#47;2 safety and efficacy data for the monotherapy in metastatic, immunotherapy-resistant NSCLC</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:14.5pt">BNT316&#47;ONC-392 is entering the pivotal clinical evaluation as part of BioNTech&#8217;s strategy to initiate multiple trials with registrational potential in 2023 and 2024 </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">MAINZ, Germany, and ROCKVILLE, Maryland, USA, June 29, 2023 (GLOBE NEWSWIRE)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8212; BioNTech SE (Nasdaq&#58; BNTX, &#8220;BioNTech&#8221;) and OncoC4, Inc. (&#8220;OncoC4&#8221;), today announced that the first patient with non-small cell lung cancer (NSCLC) has been treated in a pivotal Phase 3 trial evaluating the companies&#8217; next-generation anti-CTLA-4 antibody candidate BNT316&#47;ONC-392. The trial is part of BioNTech&#8217;s strategy to initiate multiple pivotal trials in 2023 and 2024.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The two-stage, open-label, randomized Phase 3 trial, PRESERVE-003 </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NCT05671510</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, will assess the efficacy and safety of BNT316&#47;ONC-392 as monotherapy compared to the standard-of-care chemotherapy (docetaxel) in patients with metastatic NSCLC that progressed under previous PD-(L)1-inhibitor treatment. Approximately 600 patients are planned to be enrolled at clinical sites in the United States, Europe and other countries and regions, including Belgium, Germany, Italy, Spain, and  Turkey. The primary endpoint measure will be overall survival. Secondary endpoints include overall response rate, progression-free survival and adverse event profile. The program received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in 2022 and represents an innovative approach which aims to leverage the full potential of CTLA-4-targeting therapies. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8220;We believe this investigational treatment has the potential to become a new option for patients with late-stage NSCLC who have an otherwise poor prognosis. Given its specific mode of action, this treatment approach may also be applicable in a synergistic combination with other immunotherapeutic modalities to provide benefit to further patient populations,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Prof. &#214;zlem T&#252;reci, M.D., Chief Medical Officer and Co-Founder at BioNTech</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. &#8220;We are committed to rapidly advancing our oncology pipeline towards late-stage development for multiple product candidates in cancer indications with high unmet medical need.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8220;Today represents a significant landmark for the differentiated program we developed with BNT316&#47;ONC-392, aiming to overcome current challenges of CTLA-4-targeting cancer therapeutics and in particular the very narrow therapeutic window that restricts them from delivering on their full potential,&#8221; said </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Pan Zheng, M.D., Ph.D. Chief Medical Officer and Co-Founder at OncoC4. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8220;With</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">less than three years from first in human dosing to Phase 3 initiation, we are hopeful these results will build on the responses we have seen so far.&#8221;    </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The initiation of the Phase 3 trial is based on positive safety and efficacy data from an ongoing Phase 1&#47;2 study (NCT04140526) with BNT316&#47;ONC-392 alone and in combination with pembrolizumab in patients with advanced solid tumors. Follow-up data recently presented at the ASCO 2023 Annual Meeting</font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">demonstrate an encouraging anti-tumor activity and a manageable safety profile for BNT316&#47;ONC-392 in a patient cohort with metastatic, anti-PD-(L)1-resistant NSCLC.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Phase 3 trial initiation marks the first landmark of BioNTech&#8217;s and OncoC4&#8217;s strategic collaboration initiated in March 2023. Under the terms of the collaboration agreement, OncoC4 received a $200 million upfront payment and is eligible to receive development, regulatory and commercial milestone payments as well as double-digit tiered royalties. BioNTech and OncoC4 will jointly develop BNT316&#47;ONC-392 as monotherapy and in combination with anti-PD-(L)-1 antibodies in a range of solid tumor indications until regulatory authorization, with the parties equally sharing development costs for such studies. Combinations outside of PD-1 inhibition, in particular all combinations with a compound in BioNTech&#8217;s pipeline, will be solely developed by BioNTech. BioNTech will hold the exclusive worldwide commercialization rights for any of these products with participation of OncoC4 in certain markets to be negotiated in the future. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">About BNT316&#47;ONC-39</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BNT316&#47;ONC-392  is a next-generation anti-CTLA-4 antibody candidate jointly developed by BioNTech and OncoC4. BNT316&#47;ONC-392 is currently in late-stage clinical development as monotherapy or combination therapy in various cancer indications. The immune checkpoint receptor CTLA-4 inhibits T cell immune response and reduces the activity of T cells in recognizing and eliminating cancer cells</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This mechanism is also exploited by cancer cells to prevent them from being eliminated by T cells</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Blocking CTLA-4 may help to preserve T cell activity and enhance anti-tumor activity. BNT316&#47;ONC-392 was designed with the aim to address this mechanism while  preserving CTLA-4 recycling and thus the immunosuppressive T cell (regulatory T cells, or &#8220;Tregs&#8221;) function in the peripheral tissues. This approach, which is currently in clinical evaluation, aims to give rise to fewer immune-related adverse effects and a more favorable safety profile. BNT316&#47;ONC-392 is currently being evaluated in an ongoing Phase 1&#47;2 trial, PRESERVE-001, (NCT04140526) in patients with advanced solid tumors as single agent or in combination with pembrolizumab. An ongoing registrational Phase 3 trial, PRESERVE-003 (NCT05671510) evaluates the candidate as monotherapy in patients with metastatic, immunotherapy-resistant non-small cell lung cancer (NSCLC). In addition, the candidate is also being evaluated in a Phase 2 trial as a combination therapy with pembrolizumab in platinum-resistant ovarian cancer (NCT05446298).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">About NSCLC</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Non-small cell lung cancer (NSCLC) covers all epithelial lung cancers other than small cell lung cancer and includes squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung. It is the most common type of lung cancer, accounting for up to 85% of cases</font><font style="background-color:#e6e6e6;color:#2b579a;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, with risk factors ranging from smoking to asbestos exposure and pulmonary fibrosis</font><font style="background-color:#e6e6e6;color:#2b579a;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. With a 5-year relative survival rate of 23% in the United States (2012-2018), NSCLC is a devastating disease with limited treatment options depending on the stage and location of the tumor</font><font style="background-color:#e6e6e6;color:#2b579a;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Current standard of care includes surgery, radiotherapy in combination with chemotherapy and immunotherapy</font><font style="background-color:#e6e6e6;color:#2b579a;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">About BioNTech</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab,  OncoC4, Regeneron, Sanofi, and Pfizer.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For more information, please visit www.BioNTech.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">About OncoC4 </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Based in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment. Its lead clinical candidate is BNT316&#47;ONC-392, a next generation anti-CTLA-4 antibody that allows CTLA-4 to recycle and maintain its protective function against autoimmune diseases while enhancing anti-tumor activity at the same time. In addition, OncoC4 has a pipeline of first-in-class preclinical product candidates focusing on the CD24-Siglecs cancer immune evasion pathway. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">More information&#58; www.oncoc4.com.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">BioNTech Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains &#8220;forward-looking statements&#8221; of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning&#58; BioNTech&#8217;s collaboration with OncoC4, Inc&#59; the ability of the anti-CTLA-4 monoclonal antibody candidate BNT316&#47;ONC-392 to eliminate immunosuppressive regulatory T cells and enhance anti-tumor activity in various cancer indications&#59; the development of BNT316&#47;ONC-392 as a monotherapy or combination therapy in various cancer indications&#59; the timing, size and success of a Phase 3 study evaluating BNT316&#47;ONC-392 as a monotherapy against the current standard of care in PD-1-resistant NSCLC&#59; the timing and success of a Phase 2 trial of BNT316&#47;ONC-392 as a combination therapy with pembrolizumab in platinum-resistant ovarian cancer&#59; and the timing of BioNTech&#8217;s strategy to initiate trials with registrational potential for multiple oncology </font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:70.56pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">candidates in 2023 and 2024. Any forward-looking statements in this press release are based on BioNTech&#8217;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to&#58; the ability of BioNTech to develop and, if approved, commercialize these potential immunotherapies.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For a discussion of these and other risks and uncertainties, see BioNTech&#8217;s Quarterly Report on Form 6-K for the quarter ended March 31, 2023, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on May 8, 2023, which is available on the SEC&#8217;s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONTACTS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BioNTech</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Victoria Meissner, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+1 617 528 8293</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investors&#64;biontech.de </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Media Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jasmina Alatovic</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+49 (0)6131 9084 1513</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Media&#64;biontech.de </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">OncoC4</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Martin Devenport</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mdevenport&#64;oncoc4.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Media Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Helen Schiltz</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">hschiltz&#64;oncoc4.com </font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.874%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Front Oncol. 2018 Mar 28&#59;8&#58;86 published online, doi&#58; 10.3389&#47;fonc.2018.00086.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Front. Immunol., 2021 Aug. 31&#59; Vol. 12 &#8211; 2021&#59; https&#58;&#47;&#47;doi.org&#47;10.3389&#47;fimmu.2021.651634</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CA Cancer J Clin. 2021 May </font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M"&-NC9069CS&A5<="%$(W3^ ^NRY)57H_@DI-XN-]2R_+TWWGQ/&P*3,\ &
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MGSVWI K=/R'D?[)VN!.?JWRB^W>'A]\)>5.R.5U/AVT12DMU/-OMG<?;!1!
M]T\(&9KXQ"&,N3526ICQ>+V-HUV[ 0DA4J'[!U"?/;>D"MT_(>1_<W&3PZN!
M=/^^5)>G%/^$O#7AYBV;C[5,FFT1"@SU/S31_1-"AB8^<0AC;HV4%F8\7H,?
M-R3$2^C^ =1GSRVI0O=/"/G?A+-!?+IRB.[?$;YZ1\C(66RL4_^_AFT1BDW[
M=B_>.D!2=/^$D*&)3QS"F%LCI849CZ'X<4-"'(7N'T!]]MR2*G3_A)"_)8,;
M';I_+RC^":F9^>W5/+[7,E&V12@YU/^00O=/"!F:^,0AC+DU4EJ8\7@9Q3\A
MOI+!E#B Y.RY)57H_@DA?TL&K_[3_;O 5^\(&4OF-I>I_U]F6X3"<_';-_$V
M A*A^R>$#$U\XA#&W!HI+<QXO(#BGQ!WH?L'4)\]MZ0*W3\A)([W>QVZ?WT4
M_X2,,=3_+[,M FE=K<2;"4B![I\0,C3QB4,8<VNDM##C\25A=$;Q3XB[>)\/
M!Z# GEM2A>Z?$!)GZ6 K/FFY0O<OCN*?D+&'^O\%MD4@(>__]8^'QTZ\L8#I
MHOLGA Q-?.(0QMP:*2W,>'Q6][X71F=V<Q%"Q$/W#Z ^>VY)%;I_0LAGTN[<
MQ><M/^C^E5'\$S*A4/]_B6T1R"#-U@+U/]*B^R>$#$U\XA#&W!HI+<QX6'SJ
MGQ"_H?L'4)\]MZ0*W3\AY#/9.-J-SUM^T/W+VC]KVJU$"!E7J/\_R[8(Y"G-
MUD*W=QYO,F!:Z/X)(4,3GSB$,;=&2@LS'A&*?T)<A^X?0'WVW)(J=/^$D,]D
M;G,Y/F_Y0?>OB>*?D"DDG+V[][WX\"N;;1'(\U3'L]3_2(7NGQ R-/&)0QAS
M:Z2T,./Q',4_(=Y#]P^@/GMN295_=__[9\UPNT8(&9JE@ZTPGG^*/:)R2C@S
MQ*<N)[ZG^]=#\9\V<YO+S\]=7\K&T:X][WTVX9^T__.G,.61-F'[4_\_9UL$
M$J4ZGOW8^6>\X8#):]_N7?[^'<DCK:L5>WI)DO?_^H==/.(W\8E#&'-KI+30
MDSWW+O=)0O',;Z_:J8DH2P=;=C<FY"FN?P 7@ A[A4J5?W?_\=(!>(MP%%67
MI^$6(=Q'SFTNV\/,:<(]<;RJ3GQ/]R_FXN8ZIT-#)T^#VZ?./IR+PAEID/C/
MD$X8/CTM5>.D&BSJX%$JGA*84,*&C?\,!;.U$/ELVK=[\;8#@%?[V/FG/;$D
MB:^V& "0@;7#'3LH(_43=?:-D^II;H&:%@ @R%[+4H7N'QBSBYOK<#^:1Z'E
M],U1NG\I83Q&\5\S@^'N8*RKUNN/2SAS/CT9,'@LP&X'\J:L'>[$6[E4MA8B
M7PKU/X"1T?T# ,H4AK%V.$9>G\%W"L, ]OOFC_MGS??7'RYNKN.M# " !_8R
MERIT_\"DM#MWX;9U?GO5'GA>XO2S_W3_.OC%N[=F,.C=.-H=/,_N]/F;<0FK
M'S;"X.NI8;.X/ITF2=B+XFU:)%L+D1?2NEJ)MR  O +=/P"@0-7EJ1V(D1>R
MV%@?O,<_^&QAO$$! /#,7OA2A>X?F+C]LZ;3RLKI9__I_G7PX;NA"2>'P;B7
MIO\U!D\#-$ZJL&OQ6,EK4EV>QANQ/+86(B^'^A_ ".C^ 0"EX?<-7Y/!ZPW[
M9TW>Y@< 9,]>!U.%[A^8$J=/ '@L(^G^1?#ANR]E\ %_RO[Z!H\"#'XF@#F7
MSR9L%F98;"U$AN;]O_[Q\-B)-R4 ?!G=/P"@*'SF\$N9WUY=.]QIG%0,10$
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M .,B^!D8C^>T/MW_6_SZQP]VR;VG=;42KR=DT/WGA.X? *!/\%<.G0ZR  "
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M=/^9^=CY9W4\:__0KA/VTH?'3KRJDT3WGQ.Z?P" %[)C+EYX / :.E/?=/]
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MZ?ZAI]L[SZ_^;[86'AX[\:H.0_>?$[I_ (!37A[.#MD_:\9+#Z \.E/?=/]
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M P!<VSC:M8,C\5#_ V72F?JF^P<B]C!)%;I_0)?4P,-1C:US ^1HH[V&KQ_
M&V1N<SFS-YCAB,?B?R:[$U>?[A]^M&_W[)[C/:VKE7@]GZ'[SPG=/P# -8\O
M/,Q0_P-%TIGZIOL'(O8P216Z?T"7SK$YXZH-TKD!<K317J.Z/+7KZ"+[9\UX
M98 )<UK\A[0[=_'*.&=KH22A^\=KW'S\J3J>M?N/Z[2N5AX>._&J?D+WGQ.Z
M?P" =U*S<*\/]3]0&IVI;[I_(&(/DU2A^P=TV6,D81S5V#HW0(XVVBO-;Z_:
MU701ZG],D]0OMKPI:X<[\<KX9VNA)*'[QRMU>^?YU?_-UL)GZW^Z_YS0_0,
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M'@D/PC< "A3^XAM'N\JGY?H):U?(;SW:6BA)Z/XQ":VK%;NSD1%"]U\?W3\
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M2$6R?ZB'FS]_D5/ N&3_^9#]!X,V$2+V2L?##B=78Y[;B)DZBK'MM+X=#1I
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M.ZUO1X,&4 8Y3;3\+_N_N;];OF41\0?D\U-3++-2=;DQ0 L[LZ!U_KCH_HD
MI?@R^\V"\\5U]R\#@)>7I^>9G"_E37]&]R^#[\3(I4S^_<]=]X^#[X<V$2+V
M2L<#%)$W)&*FCCI7=II^C@8-H QRFFB9IN>_0L%"C+00/OD     245.1*Y"
"8((!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
